



► PerkinElmer, Inc.
940 Winter Street
Waltham, MA 02451 USA
Phone: 781-663-6900
Fax: 781-663-5985
www.perkinelmer.com

FOR IMMEDIATE RELEASE

APRIL 1, 2008

**PERKINELMER ANNOUNCES NEW ULTRA-VIOLET/VISIBLE (UV/VIS)
SPECTROPHOTOMETERS**

Expansion of Molecular Spectroscopy Line Provides Customers with Maximum Uptime, Low Cost of Ownership, High Stability and Added Assurance of Results

MUNICH, Germany – PerkinElmer Life and Analytical Sciences, a global leader in application-focused measurement and analysis solutions, today featured at Analytica[®] 2008, April 1-4, Stand 405/504 in Hall A2 the LAMBDA[™] XLS, a UV/Vis spectrophotometer for Quality Assurance/Quality Control (QA/QC) and teaching laboratories, and the LAMBDA[™] Bio, a UV/Vis spectrophotometer designed specifically for biological science laboratories. Both the LAMBDA XLS and LAMBDA Bio are designed as low-cost, routine platforms with a number of pre-configured standard methods and the capability to add customized methods, addressing a wide range of applications.

The LAMBDA XLS, on display at the PerkinElmer booth, was designed with a focus on productivity and ease of use. The LAMBDA XLS and Bio models include a large, clear on-board display and robust spill-resistant keypad. With its intuitive graphical interface and wide range of local language options, users in manufacturing QA/QC, environmental, teaching and food analysis laboratories are able to perform wavelength, scanning, concentration studies and biological assays with ease.

“The LAMBDA XLS was developed in response to customer needs in today’s fast-paced, multitasking laboratory environment for instrumentation that generates results quickly and delivers a high level of stability and robustness,” said Martin Long, Vice President, Materials Characterization, PerkinElmer Life and Analytical Sciences. “It includes methods for many of the analytical challenges facing the global ecosystem.”

The LAMBDA Bio is pre-configured with standard methods for ease of access, including DNA, RNA and Oligonucleotides concentration and purity, protein assays and cell density measurements.

Both the LAMBDA XLS and LAMBDA Bio have no moving parts and feature an ultra-long lifetime Xenon lamp helping to ensure robustness, maximum uptime and low cost of ownership. The high quality split-beam optical design provides high stability and run-to-run reproducibility for added assurance of results.

The instrumentation is available for purchase online through the PerkinElmer Web site.

For more information on the LAMBDA XLS visit www.perkinelmer.com/lambdaxls.

For more information on the LAMBDA Bio visit www.perkinelmer.com/lambdabio.

Factors Affecting Future Performance

This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of \$1.8 billion in 2007, has 9,100 employees serving customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

#

For further information regarding PerkinElmer, please contact:

Media Contact:

Ellen Wein
Euro RSCG Worldwide PR
(412) 456-0986

or

Lesley Sillaman
Euro RSCG Worldwide PR
(412) 456-7839